Mylan, IRS Ink Deal To Avoid Trial On Nebivolol Transaction

By Jimmy Hoover · May 24, 2017, 4:23 PM EDT

Mylan Inc. and the IRS have struck a last-minute deal to avert a $100 million tax trial relating to the drugmaker's transaction with Forest Laboratories Holdings Ltd. over the antihypertensive compound...

To view the full article, register now.